Physician profile
Kate Ryan
NPI 1558865022
$2,110.62
in general payments reported to CMS, 2019-2025
28 companies · $816 in 2025
The $816 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.44 · 2021: $186 · 2022: $224 · 2023: $357 · 2024: $504 · 2025: $816.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,677.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,677.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $556.32 | 2022-2025 | Vraylar, Qulipta |
| Novo Nordisk INC | $225.39 | 2022-2025 | Ozempic, Rybelsus |
| Corcept Therapeutics | $190.43 | 2024-2025 | Korlym |
| Vapotherm INC | $117.00 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $116.84 | 2024-2025 | Caplyta |
| Amgen INC. | $95.62 | 2023-2025 | Otezla, Repatha, Repatha |
| Astrazeneca Pharmaceuticals Lp | $88.37 | 2024-2025 | Farxiga, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.40 | 2024-2025 | Xifaxan |
| Xeris Pharmaceuticals, INC. | $72.99 | 2021-2024 | Gvoke Hypopen |
| Lilly USA, LLC | $67.28 | 2022-2025 | Mounjaro, Zepbound |
| Gilead Sciences, INC. | $54.63 | 2025 | |
| Dexcom, INC. | $49.01 | 2024-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $47.15 | 2023-2025 | Freestyle Libre 3 |
| Nestle Healthcare Nutrition INC. | $34.14 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.62 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $29.24 | 2024 | Skyclarys, Spinraza |
| Exact Sciences Corporation | $28.49 | 2023-2024 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $28.34 | 2025 | Symbravo |
| Merck Sharp & Dohme LLC | $25.26 | 2019-2022 | |
| Astellas Pharma US INC | $23.92 | 2023 | Veozah |
| Supernus Pharmaceuticals, INC. | $23.10 | 2023 | Qelbree |
| Lundbeck LLC | $23.03 | 2025 | Rexulti |
| Alkermes, INC. | $22.02 | 2025 | Vivitrol |
| Neurocrine Biosciences, INC. | $20.09 | 2023 | Ingrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.56 | 2021 | |
| Pfizer INC. | $16.43 | 2024 | |
| Horizon Therapeutics Plc | $14.50 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $12.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kate Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.